George Ackerman lost his mother to Parkinson’s disease in 2020 when she was 69, and he still grieves for her. But he is also driven — to honor her, to raise awareness about the neurodegenerative disorder, and to support the search for a cure. He maintains a website, hosts…
U.S. Marine Corps and Navy personnel exposed to trichloroethylene (TCE) and other industrial chemicals in drinking water at Camp Lejeune in North Carolina face greater than twice the risk of experiencing accelerated Parkinson’s disease progression than individuals who were not exposed, a new study found. These findings add to…
Blocking the activity of a protein called activin A was shown to prevent the development of levodopa-induced dyskinesia in a mouse model of Parkinson’s disease in a recent study. “By prohibiting the protein from functioning, we were able to halt the development of dyskinesia symptoms in the mouse…
Dopamine-producing nerve cells, or dopaminergic neurons, in the midbrain may play a role in the temporary storage of information in short-term memory, according to new data from a mouse study. This finding challenges the traditional understanding of these nerve cells, which were previously thought to function primarily in reward processing…
An intensive course in the Lee Silverman Voice Treatment, known as LSVT Loud, may be the best strategy to help people with Parkinson’s disease overcome speech and language problems, according to a trial from the University of Birmingham in the U.K. LSVT Loud, a program of vocal exercises developed…
Low levels in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — of proteins associated with nerve cell function may help in the early diagnosis of people with progressive supranuclear palsy (PSP), a form of atypical parkinsonism, according…
Once-daily treatment with IRX4204, an oral small molecule being developed by Io Therapeutics, showed a potential to safely ease motor symptoms for most adults with early Parkinson’s disease taking part in a small, 30-day study. Building on this open-label Phase 1 clinical trial (NCT02438215), the company…
AskBio’s investigational gene therapy AB-1005 has been granted fast-track designation for Parkinson’s disease by the U.S. Food and Drug Administration (FDA), and innovation passport designation by the regulatory agency in the U.K. These designations are meant to accelerate the development and review process of therapy candidates designed to…
The first three Parkinson’s disease patients who received a low dose of TED-A9, an investigational stem cell-based therapy being developed by S.Biomedics, saw reduced motor symptoms after a year without any reported side effects. The results come from a small Phase 1/2 clinical study (NCT05887466) where 12…
Scientists have discovered a new regulator — called NHR-49 — that may shed light and open potential new therapeutic avenues to prevent the formation of toxic protein clumps, a hallmark of aging-related diseases, including Parkinson’s disease. Using embryos of the roundworm Caenorhabditis elegans, they found that NHR-49 is activated…
Get regular updates to your inbox.